Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2023 | The efficacy of venetoclax-based salvage therapy in patients with previously treated R/R AML

Jan Bewersdorf • 18 Apr 2023
AACR 2023
Acute Myeloid Leukemia Leukemia Venetoclax

Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses unmet needs in relapsed/refractory (R/R) acute myeloid leukemia (AML), and further explains the efficacy of venetoclax-based salvage regimens in patients with R/R AML previously treated with a FLT3 or IDH inhibitor. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jan Bewersdorf

2:00
Optimizing HMA treatment in HR-MDS: azacitidine versus decitabine
Jan Bewersdorf • 10 Dec 2023
2:48
Validation of IWG 2023 criteria for response to treatment with HMA in HR-MDS
Jan Bewersdorf • 10 Dec 2023
1:43
E7820 in combination with venetoclax in patients with splicing factor mutant myeloid malignancies
Jan Bewersdorf • 10 Dec 2023
2:36
Intensive induction chemotherapy vs HMA/Ven in NPM1-mutant AML: a retrospective study
Jan Bewersdorf • 10 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals